The Ministry of Health is working with partners to evaluate the impact of pharmacists assessing and prescribing through the Minor Ailments and Contraception Service (MACS).
This monitoring and evaluation data demonstrates the uptake and performance of MACS on patients and the health care system. The program launched on June 1, 2023.
*Submitted a PharmaCare claim in the year before program launch
The greatest number of assessments were for:
Of the minor ailment and contraception assessments, approximately 79% resulted in a prescription and 10% resulted in advice to see another healthcare provider.
Ailment | % of claims |
---|---|
Herpes labialis (cold sores) | 94% |
Urinary tract infection (uncomplicated) | 89% |
Acne | 89% |
Gastroesophageal reflux disease/dyspepsia | 88% |
Hemorrhoids | 88% |
Ailment | % of claims |
---|---|
Headache | 21% |
Shingles | 19% |
Vaginal candidiasis | 18% |
Oropharyngeal candidiasis | 18% |
Fungal infection | 16% |
The Ministry extends its appreciation to pharmacists for the ongoing success of MACS and pharmacists prescribing. For more information, refer to Pharmacist scope of practice.
The goals of the MACS evaluation are to:
As part of the evaluation plan, pharmacists and members of the public may be invited to participate in surveys. All perspectives are valued and will help the Ministry improve the program.
Check this page for ongoing updates as new data becomes available.